Skip to main content
European Commission logo print header

Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry


Genome Biologics’ novel drug discovery platform addresses the inefficiencies in pre-clinical studies with a unique combination of genomics, molecular science and big data analytics. Using patented single cell transgenic technology, the platform can express 50 different genes in a single animal in 6-8 weeks. This breakthrough approach reduces pre-clinical study time and costs by a factor of 10x, allowing pharmaceuticals companies to bring drug candidates to the stage of human trials in 3-6 months instead of 7-10 years. This drastic cost and time reduction will make it economically possible for pharmaceutical companies to bring affordable and effective treatments for rare diseases, as well as (non-orphan) non-communicable diseases, such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, which carry an increasing burden for healthcare systems treating an ageing population.
The novel platform also brings a step-change in transgenic animal models: 50-100x less animals are required to generate a reliable model, which reduces drastically the number of animals required in pre-clinical studies and the related ethical burden for pharmaceuticals companies.
The solution uses a patent protected DNA/RNA adeno-associated virus technology that enables testing of up to 50 disease-related genes in a target tissue of interest simultaneously, while at the same time ensuring that each of the cells expresses only a single gene. The technology is addressing a market where pharmaceutical companies currently spend €1Bn per year on animal models. We will interview 40 target customers in phase 1 in order to validate the market potential of the solution, and confirm our initial willingness to pay analysis. We will also identify technical improvement areas and define a go to market plan.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
Danziger weg 17
61476 Kronberg im taunus

See on map

Hessen Darmstadt Hochtaunuskreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00